Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial
First-line sintilimab plus anlotinib showed improved ORR and PFS, alongside a superior safety profile, compared to the standard platinum-based chemotherapy for metastatic NSCLC patients.
Authors
- Tianqing Chu (ORCID: https://orcid.org/0000-0002-0744-0397)
- Nan Geng (ORCID: https://orcid.org/0000-0001-8953-1438)
- Baohui Han (ORCID: https://orcid.org/0000-0002-3950-3030)
- Yanqiu Zhao (ORCID: https://orcid.org/0000-0003-0161-6184)
- Maojing Guan (ORCID: https://orcid.org/0000-0003-1009-1658)
- Jing Wang (ORCID: https://orcid.org/0000-0002-5398-0802)
- Hua Zhong (ORCID: https://orcid.org/0000-0003-1102-5820)
- Zhuang Yu (ORCID: https://orcid.org/0000-0003-1676-135X)
- Xinmin Yu
- Qingming Shi (ORCID: https://orcid.org/0000-0001-9293-2849)
- Cuimin Ding
- Jialin Qian
- Xiaoqian Mu
- Xun Shi
Institutions
- Qingdao University (CN)
- Hebei Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Shanghai Chest Hospital (CN)
- Zhengzhou University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
- Henan Cancer Hospital (CN)
- Xi'an Chest Hospital (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Cancer Communications
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1002/cac2.12654
- Citations
- 6
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- National Health Commission of the People's Republic of China